Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Seattle Cancer Care Alliance Network Investigators

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StatePublished - Jan 1 2019

Keywords

  • Circulating endothelial cells
  • Circulating tumor cells
  • Erlotinib
  • Metastatic
  • Nab-paclitaxel bevacizumab
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib'. Together they form a unique fingerprint.

  • Cite this